Brain health in an ageing population – One in three individuals over the age of 80 suffers from at least one neurological disease – Raising awareness for an underestimated problem – More prevention can mitigate human suffering and economic consequences… Continue Reading

The International Parkinson Disease and Movement Disorders Society (MDS) Task Force on Genetic Nomenclature in Movement Disorders developed an online database providing a comprehensive overview of movement disorders phenotypes linked to causative gene mutations. MDSGene was just revealed at the… Continue Reading

During the second EAN congress in Copenhagen, the current board of the EAN has been reappointed with a very strong majority and as the first president elect of the newly structured board, Franz Fazekas from Graz, Austria was elected. He will be the next president in two years from now. The board and myself thank the delegates for this confidence shown to us. We interpret this as a strong mandate to follow and expand the tracks that we have already started to follow. This is to briefly outline two of these avenues. Meanwhile, the major goals for our Society are outlined in the strategic plan.

Are you looking for an exciting opportunity to develop your professional standing, leadership skills, and to make new neuro-friends from across Europe?
Members of our standing committees kindly serve EAN for a 4-year term. Therefore, we need to renew part… Continue Reading

Finland, officially the Republic of Finland (in Finnish: Suomi), is the northernmost and the most sparsely populated country in the European Union. By size, it is the fifth-largest country in Western Europe with its 338,440 km² of land, and with a population of 5.5 million (16 persons/km²). Politically, Finland has been a parliamentary democracy since its independence 1917, after having been a grand duchy of Russian empire for 108 years and prior to that a part of Sweden for 600 years.

For July 2016 we have selected: Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomized trials. Rothwell PM, Algra A, Chen Z, Diener H-C, Norrving B, Mehta Z. Lancet Neurol 2016 May 18. doi: 10.1016/S0140-6736(16)30468-8. Whereas there is robust evidence encouraging the use of aspirin for long-term secondary prevention after transient ischaemic attack (TIA) or ischaemic stroke, data supporting aspirin treatment to reduce early recurrence of ischæmic events is weak. Moreover, even less information is available concerning the early aspirin effects on risk or severity recurrence after minor strokes.

  By Elena Moro   Video interview with Prof. A. Schapira editor-in-chief of the European Journal of Neurology was last modified: August 1st, 2016 by Editor… Continue Reading